This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CAB-175

Merck & Co., Inc.

Drug Names(s): CAB-175

Description: CAB-175 is a novel cephalosporin antibiotic. As with all cephalosporins, CAB-175 inhibits bacterial cell wall synthesis by inhibiting penicillin binding proteins.

Deal Structure: Merck and Cubist
In December 2014, Merck and Cubist Pharmaceuticals announced that the companies have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash. Unanimously approved by the boards of directors of both companies, the transaction has an equity valuation of $8.4 billion and will also include $1.1 billion in net debt (based on projected cash balances) and other considerations for a total transaction value of approximately $9.5 billion.

In January 2015, Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, at a purchase price of $102.00 per share.


CAB-175 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug